← Back to Screener
Lite Strategy, Inc. Common Stock (LITS)
Price$0.75
Value ScoreB
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-68.31%
Price vs S&P 500 (4W)-38.61%
VGM Score42.86
Market Capitalization$25.48M
All Metrics
Book Value / Share (Quarterly)$1.62
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.30
Price vs S&P 500 (YTD)-51.43%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)39.05%
EPS (TTM)$-1.74
10-Day Avg Trading Volume0.74M
EPS Excl Extra (TTM)$-1.74
EPS (Annual)$-2.39
Dividend / Share (Annual)$0.00
ROI (Annual)-94.18%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-92.08%
Cash / Share (Quarterly)$0.27
ROA (Last FY)-87.20%
EBITD / Share (TTM)$-1.96
ROE (5Y Avg)-71.43%
Operating Margin (TTM)34.86%
Cash Flow / Share (Annual)$-3.13
P/B Ratio0.45x
P/B Ratio (Quarterly)0.74x
Net Income / Employee (Annual)$-3,986,300
Net Interest Coverage (TTM)-21.51x
ROA (TTM)-67.48%
EPS Incl Extra (Annual)$-2.39
Current Ratio (Annual)13.50x
Quick Ratio (Quarterly)10.11x
3-Month Avg Trading Volume0.37M
52-Week Price Return-65.17%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)0.39x
Asset Turnover (Annual)1.58x
52-Week High$9.00
Operating Margin (5Y Avg)-100.94%
EPS Excl Extra (Annual)$-2.39
26-Week Price Return-60.38%
Quick Ratio (Annual)13.30x
13-Week Price Return-33.73%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.53x
Enterprise Value$17.93M
Asset Turnover (TTM)0.84x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)27.23%
Cash / Share (Annual)$2.70
3-Month Return Std Dev67.19%
Gross Margin (5Y Avg)38.18%
Net Income / Employee (TTM)$-9,924,800
ROE (Last FY)-94.18%
EPS Basic Excl Extra (Annual)$-2.39
P/FCF (TTM)0.35x
Receivables Turnover (TTM)1306.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.74
Receivables Turnover (Annual)1305.94x
ROI (TTM)-68.86%
P/S Ratio (TTM)0.24x
Pretax Margin (5Y Avg)-92.08%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-89.54%
Year-to-Date Return-43.27%
5-Day Price Return-21.84%
EPS Normalized (Annual)$-2.39
ROA (5Y Avg)-24.99%
Net Profit Margin (Annual)27.23%
Month-to-Date Return-25.86%
EBITD / Share (Annual)$-2.56
Operating Margin (Annual)22.27%
ROI (5Y Avg)-71.43%
EPS Basic Excl Extra (TTM)$-1.74
Payout Ratio (Annual)65.59%
P/B Ratio (Annual)0.97x
Dividend / Share (TTM)$0.00
Pretax Margin (TTM)39.05%
Book Value / Share (Annual)$2.54
Price vs S&P 500 (13W)-41.99%
Dividend Yield (TTM)0.00%
Beta0.15x
P/FCF (Annual)0.76x
Revenue / Share (TTM)$0.00
ROE (TTM)-68.86%
52-Week Low$0.70
vGradeB
mGradeF
vgmGradeC
Show chart for
Analyst Recommendations
Aug 2025
Sep 2025
Oct 2025
Nov 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LITSLite Strategy, Inc. Common Stock | B | — | F | $0.75 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Lite Strategy Inc is a clinical-stage pharmaceutical company developing novel therapies for cancer. The company's pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3K inhibitor, both designed to improve patient outcomes in oncology.